|
Colorectal Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Our results indicate that the loss of EPHB6 contributes to the metastatic process of colorectal cancer.
|
28262839 |
2017 |
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
EphB6 is upregulated in human colorectal cancer (CRC) tissues as compared to normal tissues, and its overexpression promotes proliferation, migration and invasion by IMCE colorectal adenoma cells, in which one Apc allele is mutated.
|
27145271 |
2016 |
|
Colorectal Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Low levels of EphB6 protein expression are associated with a shorter mean duration of survival in colorectal cancer.
|
24912672 |
2014 |
|
Colorectal Carcinoma
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Ovarian Mucinous Adenocarcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Glioblastoma Multiforme
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
All new compounds were tested in vitro for cytotoxic activity in a panel of human (HEP-G2, BV-173) and murine (Neuro-2a) tumor cell lines via a standard MTT-based colorimetric method.
|
30819081 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results demonstrated that high mRNA expression levels of EphB2 (HR, 0.74; 95% CI, 0.66-0.84; P=2.1×10-6), EphB4 (HR, 0.82; 95% CI, 0.72-0.93; P=0.0023) and EphB6 (HR, 0.69; 95% CI, 0.61-0.78; P=3×10-9) were significantly associated with improved survival, while a high mRNA expression level of EphB3 (HR, 1.14; 95% CI, 1.01-1.28; P=0.029) was associated with worse survival for patients with breast cancer.
|
31289549 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Remarkably, EPHB6 also suppresses tumour drug resistance to DNA-damaging therapy, probably by forcing TICs into a more proliferative, drug-sensitive state.
|
29700392 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytocompatibility of G4.0-PAMAM@HEP-mPEG nanocarriers was significantly increased compared with its parentally G4.0-PAMAM dendrimer in both mouse fibroblast NIH3T3 and the human tumor HeLa cell lines.
|
29025661 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EphA2, EphB4 and EphB6 are the members most extensively studied in breast cancer.
|
30055288 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EphB6 expression was positively associated with tumor differentiation (P< 0.001, rs= 0.476), and negatively associated with lymph node metastasis (P< 0.001, rs=-0.444) and tumor stage (P= 0.001, rs=-0.269).
|
28453458 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consistently, although EPHB6 protein expression in a series of 130 primary colorectal tumors was not associated with patient survival, EPHB6 expression was significantly lower in lymph node metastases compared to primary tumors.
|
28262839 |
2017 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EPHA7 and EPHA10 Physically Interact and Differentially Co-localize in Normal Breast and Breast Carcinoma Cell Lines, and the Co-localization Pattern Is Altered in EPHB6-expressing MDA-MB-231 Cells.
|
27566654 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor protein expression of EphA1 and EphB6 in surgically resected specimen was investigated using immunohistochemistry.
|
25391265 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously showed that EPHB6 alters the tumor phenotype of breast carcinoma cells.
|
25331796 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results indicate that tumor invasiveness-suppressing activity of EPHB6 is mediated by its ability to sequester other kinase-sufficient and oncogenic EPH receptors.
|
21737611 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A paradigm shift in EPH receptor interaction: biological relevance of EPHB6 interaction with EPHA2 and EPHB2 in breast carcinoma cell lines.
|
21737611 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
EphB6 receptor modulates micro RNA profile of breast carcinoma cells.
|
21811619 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EPHB6 mRNA and protein levels were significantly reduced in NSCLC tumors compared with matched normal lung tissue.
|
20371680 |
2010 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, increased metastatic activity is associated with reduced EphB6 receptor expression in several tumor types, including breast cancer.
|
20086179 |
2010 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we describe the relationship between loss of Ephrin receptor B6 (EPHB6) expression and the aggressiveness of breast carcinoma cell lines (BCCLs).
|
20181626 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have analysed the function of EphB6, a kinase-deficient receptor, in the invasive phenotype of breast cancer cell lines.
|
19234485 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In parallel, nude mice injected subcutaneously with HEP-2 cells were either treated intraperitoneally with sulindac or left untreated, and analyzed for tumor weight, survivin expression, and tyrosine-phosphorylated Stat3 expression.
|
17401459 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On the other hand, some tumor-suppressor genes such as EPHB6, visinin-like protein 1 (VSNL-1), and BLU were up-regulated in MIF-reduced cells.
|
16314559 |
2005 |